Cargando…

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval

Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE prevention in patients with multiple myeloma and patients with bone metastases fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cadieux, Benoit, Coleman, Robert, Jafarinasabian, Pegah, Lipton, Allan, Orlowski, Robert Z., Saad, Fred, Scagliotti, Giorgio V., Shimizu, Kazuyuki, Stopeck, Alison
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857591/ https://www.ncbi.nlm.nih.gov/pubmed/35242510 http://dx.doi.org/10.1016/j.jbo.2022.100416

Ejemplares similares

Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva)
por: Joob, Beuy, et al.
Publicado: (2014)

Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach
por: Jacobson, Dionna, et al.
Publicado: (2022)

A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva(®)) Related Osteonecrosis of the Jaw: A Retrospective Study
por: Assili, Zineb, et al.
Publicado: (2021)

Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva): First Experience
por: Rasulova, Nigora, et al.
Publicado: (2013)

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
por: Brown-Glaberman, Ursa, et al.
Publicado: (2012)

A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects
por: Ding, Yanhua, et al.
Publicado: (2023)

Impact of denosumab on bone mass in cancer patients
por: Brown-Glaberman, Ursa, et al.
Publicado: (2013)

Response to letter to the Editors—Safety of long-term denosumab therapy
por: Stopeck, Alison T., et al.
Publicado: (2016)

Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer
por: Coleman, Robert, et al.
Publicado: (2021)

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
por: Smith, M. R., et al.
Publicado: (2015)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019)

Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor
por: Coleman, RE
Publicado: (2009)

Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab
por: Lipton, Allan, et al.
Publicado: (2012)

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
Publicado: (2015)

Osteosarcopenic obesity in women: impact, prevalence, and management challenges
por: JafariNasabian, Pegah, et al.
Publicado: (2017)

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw
por: Fu, Pei-An, et al.
Publicado: (2023)

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
por: Bruni, Cosimo, et al.
Publicado: (2022)

Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity
por: Major, Pierre P, et al.
Publicado: (2009)

Denosumab-induced alopecia areata with lichenoid eruption
por: Dourra, Mohsen, et al.
Publicado: (2021)

Cost-effectiveness Analysis of Denosumab in the Prevention of Skeletal-related Events in Patients with Prostate Cancer in Kazakhstan
por: Bektur, Carina, et al.
Publicado: (2014)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)

Denosumab and muscle performance
por: Rolvien, Tim, et al.
Publicado: (2022)

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
por: Stopeck, Alison T., et al.
Publicado: (2015)

Clinical utility of denosumab for treatment of bone loss in men and women
por: Adler, Robert A, et al.
Publicado: (2011)

Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil
por: Trivedi, Ashit, et al.
Publicado: (2021)

Denosumab and atypical femoral fractures
por: Aspenberg, Per
Publicado: (2014)

Denosumab: A comprehensive review
por: Narayanan, Prasad
Publicado: (2013)

Denosumab-Induced Immune Hepatitis
por: Ostrovsky, Viviana, et al.
Publicado: (2021)

COVID pandemic and denosumab adherence
por: Minisola, S., et al.
Publicado: (2022)

A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
por: Segar, Jennifer M., et al.
Publicado: (2019)

The dilemma of denosumab: Salvage of a femoral head giant cell tumour
por: Gaston, Czar Louie, et al.
Publicado: (2014)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review
por: Kendler, David L., et al.
Publicado: (2021)

Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum
por: Bukata, Susan V., et al.
Publicado: (2021)

Treatment of facioscapulohumeral muscular dystrophy with Denosumab
por: Lefkowitz, Stanley S., et al.
Publicado: (2012)

Denosumab: mechanism of action and clinical outcomes
por: Hanley, D A, et al.
Publicado: (2012)

Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas, Kristel M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6ia44kijlcrr1824bq6rgvas9d